Celgene: The Market is all excited about their relatively modest two-month survival extension in advanced pancreatic cancer, and their planned NDA filing. Takeaway: Drugs treating terminal diseases have a low hurdle. ALS advocates will aggressively lobby for any drug that confers an additional survival benefit.
MAP Pharmaceuticals: Traded uneventfully in the high $15 range for two months and then got bought out by Allergan. Takeaway: A partnership or buyout could happen anytime for CYTK.
Amgen currently has Ganitumab in phase 3 trials for pancreatic cancer. Adding a partnership with Cytokinetics for ALS now would give Amgen a ground-floor opportunity in the event the ALS drug is successful.